Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
BRAIN Biotech AG's 3-Year RORE % for the quarter that ended in Mar. 2026 was 9.33%.
The industry rank for BRAIN Biotech AG's 3-Year RORE % or its related term are showing as below:
HAM:BNN's 3-Year RORE % is ranked better than 53.78% of 1521
companies
in the Chemicals industry
Industry Median: 6.43
vs HAM:BNN: 9.33
BRAIN Biotech AG (HAM:BNN) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
BRAIN Biotech AG 3-Year RORE % Related Terms
BRAIN Biotech AG 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for BRAIN Biotech AG's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:BNN vs LIN, SHW, ECL: 3-Year RORE % Comparison
For the Specialty Chemicals subindustry, BRAIN Biotech AG's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BRAIN Biotech AG 3-Year RORE % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where BRAIN Biotech AG's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
BRAIN Biotech AG (HAM:BNN) has a 3-Year RORE % of 9.33 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on BRAIN Biotech AG and its competitors. According to the industry distribution chart, BRAIN Biotech AG ranks #703 out of 1521 companies in the Chemicals industry, placing it in the top 46.2%.
Is BRAIN Biotech AG's 3-Year RORE % too high?
BRAIN Biotech AG's current 3-Year RORE % is 9.33. The Chemicals industry median 3-Year RORE % is 6.43. BRAIN Biotech AG's value of 9.33 is 45.1% above this industry median. Based on the distribution chart, BRAIN Biotech AG ranks #703 out of 1521 companies in the Chemicals industry, which is above the industry midpoint. Overall, BRAIN Biotech AG has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's 3-Year RORE % compare to LIN and SHW?
According to the Chemicals industry distribution chart, BRAIN Biotech AG ranks #703 out of 1521 companies for 3-Year RORE %. This puts BRAIN Biotech AG in the upper half of its industry. The industry median 3-Year RORE % is 6.43. BRAIN Biotech AG's value of 9.33 is 45.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Chemicals company?
The median 3-Year RORE % among Chemicals companies is 6.43, based on 1,521 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BRAIN Biotech AG's current 3-Year RORE % of 9.33 is 45.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on BRAIN Biotech AG and its competitors. For the Chemicals industry, the median 3-Year RORE % is 6.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BRAIN Biotech AG's current 3-Year RORE % is 9.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Fairly Valued. The stock's GF Value™ is €2.52, compared to a current price of €2.74 — trading 8.7% above its estimated fair value. The current 3-Year RORE % is 9.33 and 45.1% above the Chemicals industry median of 6.43. BRAIN Biotech AG's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current 3-Year RORE % is 9.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?
Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued.
The current stock price of €2.74 is trading 8.7% above its estimated GF Value™ of €2.52.
GuruFocus considers BRAIN Biotech AG to be Fairly Valued.
Key valuation signals for HAM:BNN:
3-Year RORE %: 9.33
GF Value™: €2.52 vs. price of €2.74 (8.7% above fair value)
Industry Position: 45.1% above the Chemicals median (#703 of 1521)
No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
68GF Score
Get the complete analysis for HAM:BNN
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BNN has been successfully added to your 
